BioSpace News Archive

Mind Medicine announced today that Prof. Matthias Liechti and Dr. Felix Mueller, MindMed collaborators at University Hospital Basel (UHB) and the University Hospital of Psychiatry, have released positive topline data from a double-blind, investigator-initiated trial evaluating lysergide in the treatment of MDD.

Phase Genomics, Inc and Element Biosciences , the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase Genomics’ proprietary OncoTerra™ cytogenomics platform and the Element AVITI System for next generation sequencing (NGS).

Akari Therapeutics, Plc announced the company will host a virtual key opinion leader event on May 22, 2023 at 2 pm ET to discuss the treatment landscape in geographic atrophy and the potential for long-acting PAS-nomacopan to address significant unmet needs.

Ocugen, Inc. today announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the Phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber Congenital Amaurosis (LCA) with mutation(s) in the CEP290 gene.

Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, will release its first quarter 2023 financial results on Thursday, May 4, after market close.

Achieve Life Sciences, Inc. (Nasdaq: ACHV) today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2023 Conference being held at the Seattle Convention Center April 25-26, 2023.

Biological Dynamics will present data showing how the company’s ExoVerita™ platform can be utilized for early detection of lung and pancreatic cancers at the American Association of Cancer Research annual meeting in Orlando, Fl., April 14-19.

Evofem Biosciences, Inc., the maker of Phexxi®, announced the appointment of Ivy Zhang as Chief Financial Officer and Secretary, effective April 13, 2023.

Harbour BioMed today announced that the results of its phase Ib clinical trial of porustobart (HBM4003) in combination of toripalimab in patients with advanced high-grade neuroendocrine neoplasms.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will present updated data from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) at the American Association for Cancer Research (AACR) Annual Meeting 2023.